When treating patients who may be eligible for hematopoietic cell transplant (HCT), you can find links here to:
On this page:
HCT offers a potential cure for blood cancers such as leukemia, lymphoma, and other life-threatening diseases. Research and resulting studies have led to expanded patient selection, more precise HLA matching between donor and patient, and more preventive strategies and improved management of complications during patient recovery and survivorship.
Because disease stage at the time of transplant can have a significant impact on patient survival, appropriate planning and early donor identification are critical for optimal outcomes.Referral timing guidelines were developed jointly by the National Marrow Donor Program® (NMDP)/Be the Match® and the American Society for Blood and Marrow Transplantation (ASBMT). These guidelines are based upon current clinical practice and the medical literature, and evidence-based reviews.
Physicians can search the Be The Match Registry® for an unrelated donor or cord blood unit on behalf of their patients needing hematopoietic cell transplantation (HCT).
A preliminary search lists potentially matched marrow donors or cord blood units at a single moment in time. It does not begin contact with, or request additional testing of, a potential marrow donor or cord blood unit. A preliminary search can be done early, while developing a treatment plan or initiating other treatment.
You can also immediately see how many potential donors and cord blood units on the registry may match your patient using the MatchView® resource.
View the latest HCT guidelines, research highlights, outcomes, and education to aid in decision-making.
Refer families who have a medical need.